Janux Therapeutics, Inc.
Janux Therapeutics is a clinical-stage biopharmaceutical company developing immunotherapies for cancer and autoimmune diseases. Its platforms include TRACTr, which produces tumor-activated T cell engagers; TRACIr, which produces tumor-activated bispecific immunomodulators; and ARM, a platform for bispecific T cell engagers designed to modulate immune responses. Janux’s clinical candidates include JANX007, a PSMA-targeting TRACTr being studied in adults with metastatic castration-resistant prostate cancer; JANX008, an EGFR-targeting TRACTr being studied for multiple solid tumors; and JANX011, a CD19-targeting ARM being evaluated in healthy volunteers for development in autoimmune diseases. Janux also develops additional pipeline programs and collaborates with biopharmaceutical companies on cancer-targeted therapies. It makes money through research funding, upfront and milestone payments, and royalties under collaboration and license agreements. Janux is headquartered in San Diego, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $JANX in the last 30 days.
See all $JANX insider activity →Barclays kept its Underweight rating on Janux Therapeutics but increased its price target to $15 from $14, suggesting a 6.6% downside from the last close of $16.06. The new target represents a 7.1% increase.
Janux Therapeutics (JANX) reported Q3 GAAP EPS of -$0.34, beating estimates by $0.14, with revenue of $9.29M, exceeding expectations by $2.87M. The company holds $945.7M in cash and investments, supporting its clinical programs.
Janux Therapeutics (JANX) dosed the first patient in a Phase 1 study of JANX013 with JANX007 and reported third-quarter 2026 results without financial figures. The company awaits November 9 data presentation for JANX011 as a potential catalyst.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning JANX (Janux Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 3 neutral, and 0 bearish.
Recent JANX coverage spans financial news, earnings and technology.
Barclays kept its Underweight rating on Janux Therapeutics but increased its price target to $15 from $14, suggesting a 6.6% downside from the last close of $16.06. The new target represents a 7.1% increase.
Earnings beat on both EPS and revenue suggests better-than-expected performance.
First‑patient dosing could lift the stock if early data are positive.
Earnings timing is the catalyst, and the article frames a potentially larger-than-usual move versus what options have priced.
First‑in‑human dosing may trigger modest short‑term price movement and sets a timeline for upcoming safety data releases.
AlphAI scores every news story that mentions JANX with an AI model for sentiment and relevance, and aggregates insider trades from Janux Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Barclays kept its Underweight rating on Janux Therapeutics but increased its price target to $15 from $14, suggesting a 6.6% downside from the last close of $16.06. The new target represents a 7.1% increase.
Janux Therapeutics (JANX) reported Q3 GAAP EPS of -$0.34, beating estimates by $0.14, with revenue of $9.29M, exceeding expectations by $2.87M. The company holds $945.7M in cash and investments, supporting its clinical programs.
Janux Therapeutics (JANX) dosed the first patient in a Phase 1 study of JANX013 with JANX007 and reported third-quarter 2026 results without financial figures. The company awaits November 9 data presentation for JANX011 as a potential catalyst.
Janux Therapeutics (JANX) may see a 6.3% stock move on its Nov. 6 earnings release, per Bloomberg options data. Historical data shows varied price movements compared to implied moves from options.
Janux Therapeutics (JANX) dosed the first patient in a Phase 1 trial for JANX013, a treatment for metastatic castration-resistant prostate cancer (mCRPC), in combination with JANX007. The study will evaluate safety, tolerability, and preliminary efficacy. JANX013 aims to enhance anti-tumor immune responses. JANX stock is up 1.81% at $17.41.
Analysts upgraded four companies: Baird raised Darden (DRI) to Outperform with a $250 target, Wolfe upgraded Janux (JANX) to Outperform with a $23 target, UBS upgraded Celestica (CLS) to Buy with a $430 target, and Wolfe upgraded PulteGroup (PHM) to Outperform with a $129 target. All companies closed at or near their respective targets on Friday.
Janux Therapeutics, Inc. (JANX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights • JANX007 Phase 1b enrollment continues across taxane-naïve monotherapy and darolutamide combination cohorts • JANX014 Phase 1 study continues enrolling patients with metastatic
Janux Therapeutics, Inc. (JANX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001817713 0001817713 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11,
Doyle Janeen Noel (Chief Corp. & Bus. Dev. Ofcr) sold 4,059 shares of Janux Therapeutics, Inc. (JANX) at $14.03 on 2026-06-02.
This article discusses the potential upside for Janux Therapeutics (JANX) as perceived by Wall Street analysts, who estimate a significant increase of 180.44%. It suggests that the stock could see substantial growth based on current analyst projections.
